Groundbreaking new drug for Alzheimer’s is going to come at a cost!

A new drug to treat Alzheimer’s has just been approved in the US but there is one big catch… it is really expensive! Priced at $56,000 for a year of treatment, the producer Biogen are being heavily criticised for charging so much for what could be a life-changing medication for the millions of Americans who suffer from the disease.

Alzheimer’s is a progressive disease which leads to loss of memory at first and then the ability to control one’s thoughts and language. The huge price tag raises ethical questions over the practice of not only Biogen, but all big pharmaceutical companies who charge extortionate prices for life-saving medication.

According to the Institute for Clinical and Economic Review (ICER), a US-based not-for-profit organisation that seeks to place a true and fair value on medical care, the new treatment should be priced at between $2500 and $8300 per year. If the calculation from ICER is even slightly accurate, this will mean huge profit margins for Biogen on the new drug.

Whilst profit maximising is the main objective for most firms, this pricing decision does reignite an age-old debate about the extreme lengths which pharmaceutical firms sometimes go to in achieving this goal. The question is: are they taking advantage of the fragile human condition to maximise profits for shareholders, or, are these firms simply responding to the invisible hand and providing a good at the price which the market has determined?

THINK LIKE AN ECONOMIST!

Q1. What is meant by the term ‘the invisible hand’?

Q2. Explain how prices for goods and services are determined.

Q3. Discuss with a friend or as part of a larger class debate whether the actions of Biogen are acceptable or not.

Click here for the source article

TheCuriousEconomist

Recent Posts

Can Defense and Housing Turn the Tide on Sluggish GDP Growth in the UK?

The U.K. economy is still stuck in low gear. The Office for Budget Responsibility (OBR)…

3 days ago

PepsiCo Plans $1.95 Billion Poppi Acquisition

PepsiCo is planning to acquire prebiotic soda brand Poppi for $1.95 billion, marking a major…

2 weeks ago

South Africa Unveils $54.5 Billion Infrastructure Plan to Boost Growth

South Africa has announced a three-year, 1 trillion rand ($54.5 billion) public infrastructure plan aimed…

3 weeks ago

Canada Pulls U.S. Alcohol from Shelves in Retaliation for Trump Tariffs

The U.S.-Canada trade war is spilling over—literally. In response to Trump’s 25% tariffs on Canadian…

3 weeks ago

U.S. Economy on Track for Contraction as Spending and Exports Decline

Early 2025 economic data suggests the U.S. economy may be slowing down faster than expected.…

4 weeks ago

India’s Consumer Market Shrinks as Wealth Inequality Deepens

India’s consumer market is far smaller than its population suggests, with only about 130-140 million…

1 month ago